|Day's Range||35.23 - 35.23|
Health and Human Services Secretary Alex Azar told Congress that at least 40 public health labs are ready to test for the coronavirus. Yahoo Finance’s Anjalee Khemlani joins Dan Roberts and Kristin Myers, along with BigEyedWish Founder Ian Wishingrad, to discuss on YFi PM.
Amgen (NASDAQ:AMGN) will present at the Cowen 40th Annual Healthcare Conference at 11:20 a.m. ET on Monday, March 2, 2020 in Boston. Peter H. Griffith, executive vice president and chief financial officer, and Murdo Gordon, executive vice president of Global Commercial Operations at Amgen will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
The U.S. Food and Drug Administration on Thursday approved Biohaven Pharmaceutical Holding Co Ltd's oral pill for relieving pain after the onset of migraine headaches, the drug developer said. Nurtec ODT, chemically known as rimegepant, belongs to an emerging class of migraine treatments called calcitonin gene-related peptide (CGRP) inhibitors and directly competes with Allergan Plc's Ubrelvy, which became the first oral CGRP to be approved for acute migraine in December. A single oral dose of the 75 mg tablet can provide fast pain relief, return patients to normal function within an hour, and remain effective for up to 48 hours for many patients, the company said.
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the second and final planned interim analysis, which included consideration of pre-specified criteria for futility and superiority. The DMC reviewed data from GALACTIC-HF and recommended that this Phase 3 clinical trial of omecamtiv mecarbil continue without changes to its conduct.
Amgen (NASDAQ:AMGN), Cytokinetics, Incorporated (NASDAQ:CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the second and final planned interim analysis, which included consideration of pre-specified criteria for futility and superiority. The DMC reviewed data from GALACTIC-HF and recommended that this Phase 3 clinical trial of omecamtiv mecarbil continue without changes to its conduct.
Investors urgently need to go forward in their value disciplines at a time when value investing has rarely looked more valuable in the marketplace Continue reading...
Amgen stock is facing concerns that biosimilars could chip away at some of its biggest moneymakers. Is it time to buy shares of the biotech company?
The Institute for Clinical and Economic Review (ICER), a small but influential Boston-based research group, has signed a deal with private technology company Aetion to help it use patient health data in its reports on whether individual drugs are priced properly. Large national regulators, including the U.S. Food and Drug Administration and United Kingdom's National Institute for Health and Care Excellence (NICE), are considering increasing the use of data gathered outside of clinical trials on the effectiveness of treatments, often referred to as real-world data. The FDA is running a pilot project using Aetion's database of insurance claims to replicate clinical trial results, as part of a requirement to comply with healthcare legislation called the 21st Century Cures Act.
People reveal more personal and intimate details to human-like apps and bots that can ‘sense’ emotions and concerns.
Some of the industry's largest pharmaceutical companies, including Pfizer Inc and Eli Lilly and Co, have developed a blockchain-based system to track prescription drugs across the supply chain to better halt the flow of counterfeit medicines, company officials said on Friday. Some two dozen companies in the industry including drugmakers, distributers, retailers and delivery firms created the blockchain-based MediLedger Network, which it has been testing in the verification of drug returns. Blockchain, which first emerged as the technology underlying virtual currency bitcoin, is a shared database maintained by a network of computers.
A venture capital firm tied to the largest health insurer in the U.S., UnitedHealth Group, has invested in a local startup working to avoid unnecessary drug costs.
Moody's Investors Service ("Moody's") assigned a Baa1 rating to the new senior unsecured note offering of Amgen Inc. ("Amgen"). There are no changes to the existing ratings of Amgen including the Baa1 senior unsecured long-term rating and the Prime-2 short-term rating. Amgen's Baa1 rating reflects its position as the largest stand-alone biotechnology company, its high margins and its good cash flow.
John Buckingham is a value-oriented money manager and editor of the industry-leading advisory service, The Prudent Speculator. Here he reviews two recommended healthcare stocks -- both large cap players in the biotechnology sector.
In a note out Thursday evening, Citi Research analyst Mohit Bansal put his money on (VRTX) the up-and-comer that analysts can’t say enough good things about. “VRTX could be the next entry in the $100B market cap club,” Bansal wrote. (VRTX) (ticker: VRTX) tops Bansal’s ranking of large-cap biotech names, a list that includes (AMGN)(AMGN), (REGN)(REGN), (GILD)(GILD), and (BIIB)(BIIB), among others.
The fast-spreading coronavirus is starting to disrupt testing of experimental medicines in China, posing a threat to plans by global drugmakers that have invested billions of dollars to harness the potential of the Asian economic powerhouse. The U.S. clinical trials database lists nearly 500 studies with a site in the city of Wuhan, which has endured the brunt of an outbreak that has killed more than 1,100 people and infected more than 44,000 in China. About 20% of global trials are now conducted in China, up from about 10% just five years ago, according to GlobalData Plc.